Jacobio Pharmaceuticals Group (1167) H2 2025 earnings summary

Executive summary

• Achieved NMPA approval and commercial launch of glecirasib (KRAS G12C) for ≥2L NSCLC in May 2025, with inclusion in the National Reimbursement Drug List by December 2025.

• Advanced clinical pipeline with multiple assets in pivotal or phase I/II trials, including pan-KRAS inhibitor JAB-23E73 and innovative ADC/iADC programs.

• Entered a major global license and collaboration agreement with AstraZeneca for JAB-23E73, securing $100 million upfront and up to $1.9 billion in milestones.

• Focused R&D on KRAS pathway and immuno-oncology, leveraging proprietary allosteric inhibitor and ADC platforms.

Financial highlights

• Revenue for 2025 was RMB53.5 million, down from RMB155.7 million in 2024, mainly from the License-Out Agreement.

• Gross profit decreased to RMB52.9 million from RMB155.7 million year-over-year.

• R&D expenses dropped 42.9% to RMB188.6 million due to reduced pivotal trial costs, with key trials funded by partners.

• Administrative expenses fell 20.2% to RMB34.4 million, reflecting cost controls and lower headcount.

• Net loss narrowed to RMB146.0 million from RMB155.7 million in 2024.

• Adjusted loss for the year was RMB138.6 million, down from RMB145.7 million.

• Cash and bank balances at year-end were RMB1,133.7 million, with no net debt.

Outlook and guidance

• Plans to expand leadership in KRAS-targeted therapies and iADC immuno-oncology, with multiple IND submissions and global trials ahead.

• Intends to strengthen R&D platforms, pursue global partnerships, and add manufacturing/commercial capabilities.

• Expects to leverage robust patent portfolio for sustained competitive advantage.